3.9 Article

Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial

Related references

Note: Only part of the references are listed.
Article Rheumatology

Recommendations for the management and treatment of systemic sclerosis

Percival Degrava Sampaio-Barros et al.

REVISTA BRASILEIRA DE REUMATOLOGIA (2013)

Article Rheumatology

Noninvasive Imaging Techniques in the Assessment of Scleroderma Spectrum Disorders

Andrea K. Murray et al.

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)

Review Rheumatology

Diagnosis and management of scleroderma peripheral vascular disease

Ariane Herrick

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2008)

Article Hematology

Effect of n-acetylcysteine on endothelial dysfunction in dialysis patients

Garip Sahin et al.

BLOOD PURIFICATION (2007)

Article Immunology

Digital ulcers in patients with systemic sclerosis

L Chung et al.

AUTOIMMUNITY REVIEWS (2006)

Article Medicine, General & Internal

High-dose acetylcysteine in idiopathic pulmonary fibrosis

M Demedts et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Review Rheumatology

Pathogenesis of Raynaud's phenomenon

AL Herrick

RHEUMATOLOGY (2005)

Review Urology & Nephrology

N-acetylcysteine in the prevention of radiocontrast-induced nephropathy

S Fishbane et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2004)

Article Rheumatology

Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma

LK Hummers et al.

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2003)

Article Cardiac & Cardiovascular Systems

N-acetylcysteine improves coronary and peripheral vascular function

NP Andrews et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2001)